Sei Investments Co. Sells 31,171 Shares of Repligen Co. (NASDAQ:RGEN)

Sei Investments Co. reduced its position in Repligen Co. (NASDAQ:RGEN) by 14.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 187,543 shares of the biotechnology company’s stock after selling 31,171 shares during the period. Sei Investments Co. owned approximately 0.34% of Repligen worth $23,641,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Dimensional Fund Advisors LP lifted its stake in shares of Repligen by 5.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 301,968 shares of the biotechnology company’s stock valued at $54,306,000 after buying an additional 16,430 shares in the last quarter. Norges Bank bought a new position in Repligen in the 4th quarter valued at about $48,208,000. Corient Private Wealth LLC boosted its stake in Repligen by 28.0% during the 4th quarter. Corient Private Wealth LLC now owns 7,011 shares of the biotechnology company’s stock valued at $1,261,000 after purchasing an additional 1,532 shares during the last quarter. Commerce Bank raised its stake in shares of Repligen by 4.5% in the fourth quarter. Commerce Bank now owns 1,683 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 72 shares during the last quarter. Finally, Intech Investment Management LLC lifted its holdings in shares of Repligen by 81.2% in the fourth quarter. Intech Investment Management LLC now owns 2,577 shares of the biotechnology company’s stock valued at $463,000 after purchasing an additional 1,155 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of RGEN opened at $142.85 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The firm has a market cap of $7.98 billion, a PE ratio of 571.40, a PEG ratio of 4.14 and a beta of 0.94. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13. The stock’s fifty day moving average price is $147.82 and its two-hundred day moving average price is $154.19.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. The business had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The company’s revenue was down 3.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.53 earnings per share. On average, equities research analysts forecast that Repligen Co. will post 1.45 EPS for the current year.

Analysts Set New Price Targets

RGEN has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and cut their price objective for the stock from $180.00 to $155.00 in a report on Wednesday, June 26th. Wells Fargo & Company assumed coverage on shares of Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective for the company. Benchmark reissued a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $190.00 target price on shares of Repligen in a report on Wednesday, July 31st. Finally, Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $188.38.

Insider Buying and Selling

In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Repligen news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the sale, the vice president now owns 19,261 shares in the company, valued at $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is owned by insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.